Axcella Health Investor Relations Material
Latest events
Q3 2022
Axcella Health
Q2 2023
3 Aug, 2023
Q1 2023
4 May, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Axcella Health Inc
Access all reports
Axcella Health Inc is a clinical stage biotechnology company in the United States. The company is focused on development of endogenous metabolic modulator compositions for complex diseases and enhanced health. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as Newco LS16, Inc. and changed its name to Axcella Health Inc. in June 2016. Axcella Health Inc. was incorporated in 2008 and is based in Cambridge, Massachusetts."
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
AXLA
Country
🇺🇸 United States